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1. Introduction 
Autoinflammatory disorders are multisystem periodic fever syndromes, and characterized 
with recurrent unprovoked inflammation of the serosal membranes. Unlike autoimmune 
disorders, autoinflammatory disorders lack the production of high-titer autoantibodies or 
antigen-specific T cells. These diseases primarily include hereditary syndromes (Table 1);  
Familial Mediterrenean fever (FMF), TNF receptor-associated periodic fever syndrome 
(TRAPS), hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS), and the 
cryopyrin-associated periodic syndrome (CAPS) which involves familial cold 
autoinflammatory syndrome (FCAS), Muckle–Wells syndrome (MWS) and neonatal onset 
multi-system inflammatory disease (NOMID)/chronic infantile neurological cutaneous and 
articular syndrome (CINCA). Familial mediterrenean fever has been considered as the most 
prevalent of innate immune system disorders involving systemic autoinflammatory reaction 
effecting joints, skin, bones and the kidney. Systemic amyloidosis is the most severe 
manifestation of the disease, commonly effecting the kidneys (11% of cases), and sometimes 
the adrenals, intestine, spleen, lung, and testis (1). As an innate immune system disorder, 
FMF is characterized by recurrent episodes of unseemingly unprovoked inflammation and 
fever with lasting 1- to 3-day attacks accompanied by sterile peritonitis, pleurisy, rash, 
arthritis, and in some cases amyloidosis leading to renal failure. this (Sohar et al., 1967). 
Apart from the typical implications of the disease, there is increasing evidence about the 
expanding clinical spectrum of FMF that embraces unusual clinical characters (2-4). These 
are the rare presentations of the disease and therefore undescores the role of molecular 
analysis in particular for the suspicious and probable cases.  
FMF is classically transmitted with autosomal recessive inheritance, and has been 
common among Mediterranean populations; however, previous reports have confirmed 
its presence worldwide. It has been described in Mediterranean populations, including 
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Italian, Spanish (5), Portuguese, French, and Greek, as well as in patients from Northern 
Europe and Japan. Nevertheless, only rare occurrences have been reported throughout the 
general population because of the low frequency of the causative alleles (6). Among 
susceptible ethnic groups, FMF prevalence is between 1/500-1/2000, and the carrier rate is 
between 16-22%. Contrary to the traditionally known monogenic inheritance of the 
disease, it has been previously evidenced that there have been a number of patients who 
have the typical FMF phenotype or FMF related symptoms with only one MEFV 
heterozygous mutation and/or even without any MEFV mutations (5-7), indicating the 
presence of clinical phenotype not only in homozygous patients, but also similarly in the 
heterozygous patients with mild disease.  
 
Syndrome (MIM) State of 
Inheritance   
Gene
(GenBank no) 
Protein Age at disease 
onset 
FMF (249100) Autosomal 
Recessive 
(dominant 
forms are rarely 
presented) 
MEFV  
(NM_000243) 
Ch-16 
Pyrin 
(marenostrin) 
Childhood  
HIDS  
(260920; 251170) 
Autosomal 
Recessive 
MVK (M88468) 
Ch-12 
Mevalonate 
kinase  
Infancy  
TRAPS 
(142680; 191190) 
Autosomal 
Dominant 
TNFRSF1A      
(NM_001065) 
Ch-12 
TNF-receptor 
type I (p55) 
Childhood 
CAPS (606416) 
- MWS 
- FCAS 
- CINCA/ NOMID 
Autosomal 
Dominant 
 NLRP3 
Ch-1 
Cryopyrin  -Childhood 
-Infancy  
-Neonatal  
PAPA Syndrome Autosomal 
Dominant 
PSTPIP1 
Ch-15 
PSTPIP1 
 
Childhood 
Blau Syndrome Autosomal 
Dominant 
NOD2/CARD15 
Ch-16 
NOD2/CARD15 
 
Childhood 
*CINCA, chronic infantile neurological, cutaneous, and articular syndrome; FCAS, familial cold autoinflammatory 
syndrome; FMF, familial Mediterranean fever; MWS, Muckle-Wells syndrome; NOMID, neonatal onset 
multisystem inflammatory disease; PAPA, pyogenic sterile arthritis, pyoderma gangrenosum, and acne;  
CAPS, cryopyrin-associated periodic syndrome; TRAPS, tumour necrosis factor receptor-associated periodic 
syndrome.  
Table 1. Hereditary autoinflammatory syndromes with identified gene loci (adapted from Lachmann 
and Hawkins, 2009: 36).  
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16p13.3 chromosomally located MEFV (Mediterranean Fever) gene has been found 
responsible for FMF disease, and the protein product, Pyrin, is a 781-amino-acid protein (8-
11). Evolutionary conserved domains of pyrin protein involves N-terminal pyrin domain, a 
B-box zinc-finger, a coiled coil and a C-terminal B30.2 PrySpry domains. Pyrin protein has 
been reported as a component of the inflammasome complex with both pro-inflammatory 
and anti-inflammatory role in the cytokine regulation (10-13). Thus, a proapoptotic or 
antiapoptotic role have been still not precise for the pyrin protein in NF-kB activation and 
apoptosis (11-16). By means of its PYD and B30.2 interacting domains, pyrin has been shown 
to bind different proteins of autoinflammatory disease genes. Each interacting protein that 
binds through the pyrin domains (PYD) consists of PSTPIP1 (17), 14-3-3 (18), Caspase-1 (19), 
ASC (20), and Siva (21). 
In 1997, The International FMF Consortium and The French FMF Consortium reported four 
missense disease associated mutations in the MEFV gene involving M694V, M680I, V726A, 
and M694I. Major and minor mutations of MEFV gene are well documented in INFEVERS, 
the database of hereditary autoinflammatory disorder mutations, and exons 2 and 10 
comprises the hot-spots (22). To date, mutations have been mostly identified in exons 2, 3, 5, 
and 10 of the MEFV gene. According to previous reports by Touitou I. (2001), and by the 
Turkish FMF study group (2005), the most common MEFV mutation in Turkey is M694V 
(57.0 and 51.4%, respectively), followed by M680I (16.5 and 14.4%, respectively), and V726A 
(13.9 and 8.6%, respectively). Moreover, no correlation has been reported between various 
MEFV gene mutations and the severity of the phenotype in various populations supporting 
the genotypic and phenotypic heterogeneity present for FMF (5, 23-25).  
According to INFEVERS (22), the database of hereditary autoinflammatory disorder 
mutations, To date, approximately 222 sequence variants including both missense mutations 
(only one nonsense mutation; Y688X) and polymorphisms have been defined in the FMF 
gene (MEFV), INFEVERS, 100 of them was clinically associated with the phenotype, 33 of 
them was not associated with the disease and the remaining was of uncertain pathogenicity. 
The remarkably wide clinical variability of the disease, as indicated by previous reports, has 
been linked to the MEFV allelic heterogeneity that underlies genotypic and phenotypic 
heterogeneity (23, 26, 27), and this has made detailed mutation screening critically 
important. In particular, Turkish FMF patients are characterized by an increased genetic 
heterogeneity due to various mutation frequencies from different regions, explained by the 
intrapopulation differentiation. 
With respect to our mutation screenings, a previous comprehensive study was performed 
with 3430 Turkish individuals from all regions of Turkey (ages range from 2 months to 67 
years; 2101 females and 1329 males) including first and second-degree relatives of 
individuals with FMF clinical diagnoses (including suspicious, possible, and definitive 
cases) who referred to the Molecular Medicine Laboratory for genetic diagnosis between 
years May, 2005 and December, 2010. The Tel-Hashomer and Livneh criteria were used for 
the clinical diagnosis of FMF based on the model of major, minor, and supportive criteria, 
which stipulates the presence of either 1 major or 2 minor criteria or 1 minor and 5 
supportive criteria for a diagnosis. A simple set of criteria for the diagnosis of FMF required 
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1 or more major and/or 2 or more minor criteria (28). None of the patients with FMF had an 
immunological disorder or another rheumatic disease. Active clinical presentations (fever, 
abdominal pain, arthritis, and myalgia) and laboratory parameters (high levels of serum 
amyloid A [SAA], C-reactive protein [CRP], fibrinogen, white blood cell [WBC] counts and 
erythrocyte sedimentation rates [ESR]) were determined for each patient. For the detection 
of all coding and non-coding sequence variations along the MEFV gene, we performed 
bidirectional DNA sequencing analysis in all 10 coding exons and exon-intron boundaries of 
the respective gene, and reported frequencies of common and rare nucleotide substitutions 
and synonymous and non-synonimous single nucleotide polymorphisms obtained in the 
Turkish population (7).  
2. Methods 
2 ml peripheral blood was collected into ethylenediaminetetraacetic acid (EDTA)-
anticoagulated tubes by the standard venipuncture method and DNA was extracted using 
the QIAamp DNA Blood Isolation kit (Qiagen GmbH, Hilden, Germany) following the 
manufacturer’s instructions. The extracted DNA concentration was determined using a 
Thermo Scientific NanoDrop spectrophotometer (Wilmington, USA). The quality 
assessment of the extracted DNA was determined by 2% agarose gel electrophoresis.  
2.1. FMF strip asay - Reverse hybridization multiplex PCR 
Reverse hybridization assay (FMF StripAssay, Viennalab Labordiagnostika GmbH) was 
used to investigate the mutations. According to the manufacturer’s instructions, in a first 
step multiplex PCR was performed using biotinylated primers for exons 2, 3, 5, 10 
amplification. PCR products were selectively hybridized to a test strip presenting a paralel 
array of allele-specific oligonucleotide probes which includes 12 MEFV mutations [E148Q, 
P369S, F479L, M680I (G/C), M680I (G/A), I692del, M694V, M694I, K695R, V726A, A744S, 
R761H]. Hybridizations were illuminated by the reaction of streptavidin-alkaline 
phosphatase and color substrate. 
2.2. DNA sequencing strategy  
Hot-spots, exons 10, and 2; with 3 and 5, and when necessary exons 1, 4, 6, 7, 8 and 9 of the 
MEFV gene were analyzed for MEFV mutations by PCR amplification followed by 
automated DNA sequence analysis. One microliter (100 ng) of genomic DNA was added to 
Polymerase Chain Reaction (PCR) amplification buffer containing 20 mM Tris (pH 8.3); 50 
mM KCl; 1.5 mM MgCl2; 0.2 mM each of dATP, 2’-deoxycytidine 5’-triphosphate, dGTP, 
and 2’-deoxythymidine 5’-triphosphate; 10 pmol each of reverse and forward primers 
provided by Invitrogen; and 1.0 U of PlatiniumTaq DNA Polymerase (Invitrogen, Carlsbad, 
CA) in a total volume of 25 µl. The cycling conditions included a hot-start denaturation step 
at 95°C for 10 min, followed by 35 amplification cycles of denaturation at 95°C for 30 s, 
annealing at 61°C for exon 10, 58°C for exons 2 and 3, or 57°C for exon 5 for 40 s, and 
elongation at 72°C for 45 s; a final extension was performed at 72°C for 7 min (the 
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oligonucleotide sequences are available upon request). Prior to sequencing, PCR products 
were purified using an ExoSAP-IT PCR Product Clean-Up kit. BigDye Terminatorv3.1 Cycle 
Sequencing Kit (Applied Biosystems, San Diego, CA, USA) was used in cycle sequencing 
reactions. Cycle sequencing PCR  products followed purification with the BigDyeXT 
kit(Applied Biosystems,) and the data were analyzed using an ABI3130xl Genetic Analyzer 
(Applied Biosystems). DNA sequencing was performed in both directions, initiated from the 
forward and reverse primers that were used in the initial PCR reaction. SeqScape 2.0 
sequence analysis software (Applied Biosystems, San Diego, CA, USA) was employed for 
sequence evaluation.  
2.3. Restriction fragment length polymorphism analysis (RFLP) 
A RFLP was identified in the mutation site and was utilized for mutation detection. 
Amplicons encompassing exon 5 were digested with the restriction enzyme Tsp509I, and 
electrophoresed on a 1% agarose gel. 
3. Results  
We found that M694V accounted for the majority of FMF chromosomes (44%), followed by 
E148Q (19%), V726A (10%), M680I (10%), P369S (4%), R408Q (3%), K695R (2%), M694I and 
R761H (1.6%), A744S (1.4%), and F479L (0.09%) (Tables 2, 3). Missense disease-causing 
mutations and synonymous polymorphisms accounted for 38% and 54% of MEFV 
chromosomes, respectively. Among the Turkish general population, the most frequent 
healthy heterozygous carrier mutation was found E148Q (6.9%), and the carrier rate was 
found 16%, with a mutation frequency of 8% (Berdeli et al., 2011). Except for the known 
major FMF mutations, by DNA sequencing, we frequently detect additional rare and novel 
mutations and critical SNPs about which we have only limited information in Turkish FMF 
patients. Remarkable consequences of sequencing analysis have been found relative to 
mutation-SNP combination underlying the combined existence of nucleotide variations in 
the same haplotype.  
For patients whose MEFV gene does not contain mutations of exons 2, 3, 5, and 10, we 
performed bidirectional DNA sequencing also in exons 1, 4, 6, 7, 8, and 9. However, we 
could not find any disease related mutation except for an exon 9 homozygous SNP, P588P, 
which is thought to be symptomatic with disease relation. This SNP was always in 
homozygous state and was not seen in combination with any of the major and minor 
mutations or any of the SNPs in the entire coding and non-coding regions of the gene. 
Relative to our experiences, this SNP has a disease relation to a minor degree, however 
possible validation of other autoinflammatory disease gene mutations should need to be 
considered. Single P588P SNP was associated with continuously high SAA levels and 
musculoskeletal complications which has a good response to colchicine in a three-member 
family who did not have any sequence variations along other coding and non-coding 
regions of the MEFV gene.  
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Genotype   
MEFV Mutation 
Number 
of 
Patients 
Genotype 
Frequency 
Exon 2 Exon 3 Exon 5 Exon 10 No (%) 
   M680IG-C/Wt 69 5.24 
   M680IG-A/Wt 5 0.37 
   M680IG-C/M680I 12 0.91 
   M680IG-C/V726A 23 1.74 
   M680IG-C/ M694V 42 3.19 
E230K   M680IG-C/ M694V 2 0.15 
   M680IG-C/A744S 1 0.12 
   M680IG-C/ R761H 2 0.15 
E148Q   M680IG-C 4 0.3 
E167D  F479L M680IG-C 1 0.07 
E167D  F479L  2 0.15 
  F479L/Wt  1 0.12 
   M694V/Wt 322 24.4 
   M694V/M694V 91 6.91 
   M694V/V722M* 1 0.12 
   M694V/V726A 42 3.19 
   M694V/R761H 5 0.37 
   M694V/K695R 2 0.15 
   M694V/A744S 1 0.12 
R241K   M694V/ 1 0.12 
E230K   M694V/ 3 0.22 
E148Q P369S  M694V 1 0.12 
E148Q/S179N*   M694V 1 0.12 
E148Q/Wt    237 18 
E148Q/E148Q    19 1.44 
E148Q   M694V 42 3.19 
E148Q   L709R 1 0.12 
E148Q P369S   4 0.3 
E148Q   V726A 7 0.53 
E148Q   A744S 1 0.12 
E148Q   M694I 7 0.53 
E148Q   K695N 1 0.12 
E148Q   R761H 4 0.3 
E148Q   I72OM 2 0.15 
E148Q/L110P    6 0.45 
E148Q/R151S    1 0.12 
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Genotype   
MEFV Mutation 
Number 
of 
Patients 
Genotype 
Frequency 
Exon 2 Exon 3 Exon 5 Exon 10 No (%) 
E148Q   K695R 2 0.15 
E148Q/T267M    1 0.12 
E148Q/E230K    4 0.3 
E148Q/T267I    1 0.12 
E148Q/L110P   M694I 1 0.12 
E148Q P369S/R408Q   18 1.36 
E148Q P369S/R408Q  M680I 1 0.12 
   M694I/A744S 1 0.12 
   V726A/Wt 111 8.43 
   V726A/V726A 4 0.3 
E167D   V726A 3 0.22 
   V726A/M694I 2 0.15 
   V726A/R761H 3 0.22 
   V726A/R761H/ M680IG-C 1 0.12 
   V726A/K695R 1 0.12 
  F479L V726A  3 0.22 
   K695R/Wt 38 2.88 
   A744S/Wt 19 1.44 
 P369S/Wt   7 0.53 
 P369S/R408Q   40 3.03 
 P369S/R408Q  M694V 4 0.3 
   M694I/Wt 10 0.75 
   R761H/Wt 31 2.35 
   R761H/ A744S 1 0.12 
   R653H/Wt 1 0.12 
   E685K/E685K 1 0.12 
L110P/L1010P    1 0.12 
E230K/E230K    1 0.12 
E230K/ Wt    1 0.12 
T267M/Wt    3 0.22 
R241K/R241K    1 0.12 
E148V/Wt    5 0.37 
E148L/Wt    2 0.15 
E167D/Wt    2 0.15 
 P350R/Wt   1 0.12 
 P350R  A744S 2 0.15 
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Genotype   
MEFV Mutation 
Number 
of 
Patients 
Genotype 
Frequency 
Exon 2 Exon 3 Exon 5 Exon 10 No (%) 
  G456A/Wt  1 0.12 
  S503C/Wt  2 0.15 
  I506V/Wt  1 0.12 
  Y471X/Wt  1 0.12 
 G340R/Wt   1 0.12 
S141I/Wt    3 0.22 
S166L/Wt    2 0.15 
  A511V/Wt  1 0.12 
 R354W/Wt   1 0.12 
 S339F/Wt   4 0.3 
 R329H/Wt   3 0.22 
 R329H/  M694V 1 0.12 
E148Q R329H/   1 0.12 
Heterozygotes     885 67.2 
Compound 
heterozygotes 
   271 20.5 
Homozygotes     130 9.87 
Complex 
genotypes 
   30 2.27 
Total number 
of patients 
with 
mutations 
   1316 38.36 
No mutation 
or SNPs 
identified 
   231 6.7 
Total number 
of patients 
with only 
SNPs 
(+R202Q) 
   1883 54.8 
Total number 
of patients 
   3430 100 
*, novel mutations 
Table 2. DNA sequencing results of MEFV genotyping among 3430 Turkish patients.  
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Mutation Number of Alleles (No) Allelic Frequency (%) 
M694V 908 44.7 
E148Q 386 19 
V726A 204 10 
M680IG-C 170 8.3 
P369S 75 3.69 
R408Q 63 3.1 
K695R 43 2.11 
M694I 21 1 
R761H 47 2.31 
A744S 26 1.28 
E148V 5 0.24 
E167D 8 0,39 
T267M 4 0.19 
L110P 8 0.39 
R241K 3 0.14 
I720M 2 0.09 
E230K 12 0.59 
M680IG-A 5 0.24 
E148L 2 0.09 
F479L 7 0.34 
E685K 2 0.09 
R653H 1 0.04 
T267I 1 0.04 
V722M  1 0.04 
S141I 3 0.14 
S339F 4 0.19 
R151S 1 0.04 
I506V 1 0.04 
S503C 2 0.09 
L709R 1 0.04 
K695N 1 0.04 
P350R 3 0.14 
G340R 1 0.04 
G456A 1 0.04 
Y471X 
R329H 
S166L 
S179N 
A511V 
R354W 
1
5 
2 
1 
1 
1
0.04 
0.24 
0.09 
0.04 
0.04 
0.04 
Total 2033 100 
Table 3. Allelic frequencies of totally 40 MEFV mutations involving major, rare and, novel sequence 
changes among the detected mutations in 1316 mutation positive patients group (mutation frequency 
for the studied mutations; complex alleles excluded).  
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Additionally, sequence analysis revealed that there was a single FMF-associated mutation in 
the MEFV coding region of 76% of the Turkish individuals studied, and 80% of these 
individuals initiated colchicine treatment following molecular diagnosis. The prevalence of 
a single mutation in patients experiencing a pathogenic effect in Turkey (76%) is contrary to 
the expected pattern of autosomal recessive inheritance and does not support the 
‘’heterozygous advantage’’ selection theory. However, the expression of the FMF phenotype 
may be influenced by other candidate modifier gene loci, autoinflammatory pathway genes 
or FMF-like diseases (29-31). For this reason, genome-wide association studies involving 
more patients should be performed and the data included in future investigations covering 
critical coding and noncoding gene SNPs for Turkish FMF patients.  
As an ancestral population of FMF, Turkey was one of the regions which involves most of 
the rare and novel mutations. As referenced in INVEFERS, most of the rare mutations in 
view of the ethnic origins were found to be symptomatic. Novel Y471X mutation found in 
the present study was the second nonsense mutation in FMF era. Among the newly 
identified mutations, involving R151S, S166N, S179N, and G340R; P350R, G456A, Y471X, 
S503C, I506V, L709R and K695N; Y471X, R151S, L709R, and K695N were observed as 
pathogenic reflecting the typical FMF character. The main clinical characteristics of the 
patients were as follows: abdominal pain (92.1%), fever (93.9%), thoracic pain (59%), 
myalgia (67.8%), arthritis (55.1%), erysipelas like erythema (ELE) (21.8%). None of the 
patients developed amyloidosis. This finding verifies the importance of molecular diagnosis 
and detailed sequencing which is recommended to perform in particular for the ancestral 
populations of FMF.  
In this report, from a large scaled heterogeneous group of patients, we describe a 44-year-
old Turkish patient from Western Turkey with clinical diagnosis of periodic fever. The case 
presented here is a 44-year-old Turkish woman, from western Turkey. The course of the 
patient includes short and rare episodes of fever, ongoing abdominal pain, temporary 
myalgia and arthralgia since her childhood. Physical examination revealed no pathology 
except for arthritis on the right knee. Her weight, height, and blood pressure were normal. 
Primarily, she had diagnosed as having conditions secondary to FMF. Although family and 
relatives screening are of great importance, her family (parents are dead in an accident) and 
past history were noncontributory and unhappy. She had undergone antibiotherapy, steroid 
treatment and appendectomy. Laboratory tests revealed the acute phase reactants as 
follows; ESR 81 mm/h, SAA 76 mg/dl, CRP 3.46 mg/dl, and fibrinogen 526 mg/dl. Renal 
function tests and other biochemical parameters were normal. No molecular genetic 
diagnosis was done except for Strip Assay in other centers. The clinical figure associated 
with her was not much contributed to the start of colchicine not fulfilling most of the clinical 
criteria, so in our laboratory, FMF strip assay was used as the first stage of mutation 
detection method involving 12 common mutations. However, no particular mutation was 
identified. Thereafter, DNA sequence analysis revealed the responsible nonsense mutation, 
p.Y471X, in MEFV gene (Figure 1). By means of the molecular diagnosis, colchicine therapy 
(1.5 mg/day) was started properly. She had no symptoms after the colchicine therapy and 
had a good response to 1,5 mg/d, and the acute phase reactants were completely normal in 
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the last 3 years. So, other autoinflammatory genes, MVK, TNFRSF1A, CIAS1, were not 
considered to evaluate as the suspicious genes in this case and were not evaluated as 
molecular diagnostics.  
 
Figure 1. Electropherogram of the p.Y471X nonsense mutation in the MEFV gene revealed by DNA 
Sequencing analysis in the Turkish patient. 
The case presented here was one of the patients who had misdiagnosis in particularly 
during the childhood losing time by unnecessary processes and treatments. Therefore, 
certain diagnosis determined by detailed DNA sequence analysis is essential for suspicious 
and undefined cases, and for cases disestablished by other limited screening methods. In the 
molecular analysis of Mediterranean fever gene, c.1413C>A nucleotide change in exon 5 
resulting in p.Tyr471X nonsense mutation was determined (Figure I). We also exploited the 
fact that the p.Y471X creates a novel recognition site for the Tsp509I restriction enzyme to 
develop a PCR-RFLP assay in order to screen the affected families and healthy controls for 
the mutation. 
Y471X nonsense mutation in MEFV gene is the first noted in Turkish FMF patients (7), and 
the second nonsense mutation of FMF mutation database worldwide. Inherited missens 
mutations reported in the 5th exon of MEFV gene in FMF patients are very rare. Though the 
fifth exon of the gene could not called as a critical region carrying the mutational hotspots, 
the result could demonstrate there is still way to walk on the road through the hidden side 
of FMF. Novel Y471X mutation in exon 5 of the MEFV gene located in the coiled coil domain 
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of pyrin protein is implicated in association with actin binding interacting selectively with 
monomeric or multimeric forms of actin. Since effects of nonsense mutations in the amino 
acids are known damaging and pathogenic,  we did not use the PolyPhen software (32) in 
order to evaluate the potential pathogenicity of this newly found amino acid substitution 
which we carry out regularly in our laboratory. Nevertheless, expression studies will be 
required.  
Due to the abundance of mutations in exon 10 and clinical heterogeneity of the disease, 
different screening methods have been developed. As long been known the majority of FMF 
patients in classically affected populations were screened by routine methods for only 
common mutations, which primarily targets only the most prevalent MEFV mutations in a 
specific population; thus, rare or novel mutations can be overlooked. The first nonsense 
mutation in FMF era, Y688X, was evaluated by Touitou I. (5),  and was suggested to have a 
location between two well-known hotspots for FMF mutations (codons 680 and 694) in exon 
10. This finding contributed to the critical role of exon 10 for the MEFV function as an 
hotspot. Here, it is discussed that, the newly found Y471X nonsense mutation has a great 
significance in screening asymptomatic individuals since it was not found in one of the hot-
spots of MEFV gene.  
Autoinflammatory diseases are heterogeneous group of disorders, thus FMF like 
phenotypes and related genes most likely exists (33-36). In some cases, the causal genes may 
not only be the unique causes of the diseases. It is well known that Mendelian disorders 
caused by the dysfunction of a single gene have a wide heterogeneity of disease phenotypes 
(37). FMF has both genetic and phenotypic heterogeneity and mutations within a single 
gene are known to cause different clinical phenotypes in Turkey. Thus, all MEFV gene 
sequence variations found in symptomatic cases should not be considered as causative 
pathogenic disease mutations. In particular, FMF related Turkish patients with no MEFV 
mutation or with only single MEFV mutations may not actually reflect the phenotype seen 
in FMF. 
Another point is subclinical inflammation concerning asymptomatic heterozygous patients 
without a second mutation mostly continues with the typical disease characteristics possibly 
due to the presence of other modifier genes and/or environmental factors. Therefore, factors 
other than casual MEFV gene and other pyrin-dependent effects should be contributing to 
the sustainable systemic inflammation that is sufficient for the occurrence of the 
symptomatic FMF related phenotype. Previously, MICA, TLR2 and SAA loci were shown as 
modifying alleles in FMF (5, 38). Synonimous or non-synonimous sequence variations of 
MEFV relevant genes involving SAA and TLR2 were previously considered as critical 
factors for the course of the disease. Both SAA1 locus and Arg753Gln TLR2 polymorphism 
were implied as genetic susceptible loci for a risk factor of developing secondary 
amyloidosis in different ethnic populations of FMF patients (26, 27, 30). Against the 
traditionally considered monogenic inheritance pattern, compound heterozygotes of 2 
autoinflammatory disease genes were also reported describing patients who were found to 
have 2 or more reduced penetrance mutations, involving E148Q in MEFV, R92Q or P46L in 
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TNFRSF1A, V377I in MVK, and V198M in CIAS1 (29, 34, 35). For the purpose of screening 
mutations in other known autoinflammatory genes for typical FMF patients carrying 1 
single heterozygous MEFV mutation, Booty et al screened 6 candidate genes that encode 
proteins known to interact with pyrin or genes functioning in IL-1B pathway involving  
ASC/PYCARD, SIVA, CASP1, PSTPIP1, POP1, and POP2 (6). A novel PSTPIP1 nucleotide 
mutation, two novel substitutions in ASC/PYCARD and SIVA genes were identified while 
Casp1, POP1, and POP2 were mutation negative. In a Jewish patient with FMF, novel 
W171X (513G>A) mutation was identified which is presumed as a stop codon, to remove the 
last 2 of the 6 helices in the CARD domain of ASC/PYCARD. In FMF patients with only 1 
MEFV mutation, including milder FMF-associated mutations, 1 Turkish patient was 
identified as a carrier of W171X  (6). To date,  SNPs in ASC/PYCARD gene were identified in 
5’/3’ region, exon 1, intron 1, exon 3 coding region involving rs79351176, rs8056505, 
rs11648861, rs79464842, rs73532217, rs75471387, rs11867108, rs61086377, rs76878620, and 
rs75216100. In the ASC/PYCARD protein, the conserved PyD domain is 91 aa in lenght (1-
91) and CARD domain is 89 aa in lenght (107-195). The previously reported W171X  
(513G>A) mutation (31) corresponds to the exon 3 coding region of the ASC/PYCARD gene 
and results with a stop codon. Thus, in our sequencing analysis, we also searched the 
presence of mutations in the ASC/PYCARD gene in our entire patients group. However, this 
sequence was not mutated, and we have neither identified the above substitutions along the 
entire coding regions and flanking segments of ASC/PYCARD gene (unpublished data).  
For investigating of mutations in other periodic fever disease genes, in a study of our group, 
a total of 75 Turkish patients and 25 ethnically matched healthy control individuals 
diagnosed with periodic fever was molecularly diagnosed for having mutations in causative 
disease genes (apart from the present patients group; unpublished data). Mutation screening 
of coding and noncoding regions of MVK, TNFRSF1A, and NLRP3/CIAS1 genes were 
carried out for different group of patients according to their clinical implications.  
MVK gene transcript variant 1 (12q24; NM_000431.2→NP_000422.1) was fully sequenced in 
25 periodic fever patients. Molecular diagnosis revealed the following results: p.Ser52Asn 
missense mutation was identified in 6 patients. In addition, p.Asp170Asp and p.Ser135Ser 
synonimous aminoacid mutations and IVS6-18 A>G, homozygous IVS9+24 G>A, and IVS 
4+8 C/T intronic nucleotide substitutions were observed in the remaining patients group.  
NLRP3 gene (CIAS1; 1q44; NM_004895.4→NP_004886.3) NACHT, LRR and PYD domains-
containing protein 3 isoform a was fully sequenced in 25 periodic fever patients. Molecular 
diagnosis revealed the following nucleotide substitutions in the screened gene region: 
K608fsX611 frameshift mutation, p.Ser726Gly and p.Gln703Lys missense mutations, 
together with Ser34Ser, Ala242Ala, Arg260Arg, Thr219Thr ve Leu411Leu synonimous 
aminoacid mutations.  
TNFRSF1A gene (12p13.2; NM_001065.3→NP_001056.1) tumor necrosis factor receptor 
superfamily member 1A precursor form was fully sequenced in 25 periodic fever patients. 
Molecular diagnosis revealed the following nucleotide substitutions in the screened gene 
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region: p. Arg92Gln and p. Ala301Thr missense mutations with IVS6+10 A>G and IVS8-23 
T>C intronic nucleotide substitutions.  
Intronic nucleotide substitutions and synonimous aminoacid mutations of all the screened 
gene regions were also observed in the 25 ethnically matched healthy control individuals. 
Mutation frequency was 4% (1/25), 32% (8/25), and 40% (n:10/25) in TRAPS, HIDS, and 
CAPS patients.  
Nonetheless, finding of symptomatic rare MEFV mutations in particular for at-risk 
populations and the individuals who have been asymptomatic and negative for common 
mutations makes detailed mutation screening critically important in FMF. It has been 
previously evidenced that there have been a number of patients who have typical FMF 
phenotype or FMF related symptoms with only one MEFV heterozygous mutation and/or 
even without any MEFV mutations (6, 7).  
The majority of FMF patients in classically affected populations are screened by routine 
methods that are limited to the detection of common mutations. These tests primarily target 
the most prevalent MEFV mutations to rule out asymptomatic cases in at-risk populations. 
Therefore, while searching for the common mutations that underlie typical FMF symptoms, 
we should primarily consider the entire coding sequence of the MEFV gene before 
analyzing other recurrent fever genes. Patients with no mutation or with only single pyrin 
mutations may not actually reflect the phenotype seen in FMF. Compound heterozygotes of 
2 autoinflammatory disease genes involving MEFV, TNFRSF1A, CIAS1, and MVK were 
reported (29, 34, 35). Thus, screening of other autoinflammatory disease genes, e.g. CIAS, 
were considered for the MEFV gene mutation/SNP negative FMF patients. In conclusion, by 
using sequencing analysis, we can prevent less common, population-restricted, novel 
sequence variants from being overlooked. This has implications for the characterization of 
typical and atypical FMF; screening for the most common mutations by routine methods is 
sufficient for the initial laboratory diagnosis of FMF in Turkish patients; however, the results 
should be confirmed by specific DNA sequencing of all coding exons and exon-intron 
flanking regions.  
4. Conclusions   
Among the newly identified mutations in this comprehensive study, Y471X, R151S, L709R, 
and K695N were observed as pathogenic reflecting the typical FMF character involving 
abdominal pain, fever, thoracic pain, myalgia, arthritis, and erysipelas like erythema. Rare 
mutations and SNPs have great importance for FMF pathogenesis. For this periodic fever 
disorder, heterogeneity is present in phases of allelic, frequency and critical locations of 
mutant alleles, and clinical appearance. Therefore, in particular for the suspicious cases; 
possible presence of other autoinflammatory disease gene mutations as we outlined above 
and rare mutations and SNP variations in the MEFV gene, molecular techniques, sample 
sizes, ethnic origins, and regions in the ancestral countries should be regarded as critical and 
determinative keys in FMF clinical and molecular diagnosis.  
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Sequencing analysis not only the common major mutations but also the detection of rare 
mutations can be carried out which have great importance in particular for at-risk 
populations. By means of sequencing analysis, we could prevent the missing of less 
common rare variants that might be restricted to the populations by routine techniques. The 
majority of FMF patients in classically affected populations are screened by routine methods 
that are limited to the detection of common mutations. These tests primarily target the most 
prevalent MEFV mutations to rule out asymptomatic cases in at-risk populations. Therefore, 
while searching for the common mutations that underlie typical FMF symptoms, we should 
primarily consider the entire coding sequence of the MEFV gene before analyzing other 
recurrent fever genes. In conclusion, by using sequencing analysis, we can prevent less 
common, population-restricted, novel sequence variants from being overlooked. This has 
implications for the characterization of typical and atypical FMF; screening for the most 
common mutations by routine methods is sufficient for the initial laboratory diagnosis of 
FMF in Turkish patients; however, the results should be confirmed by specific DNA 
sequencing of all coding exons and exon-intron flanking regions. We should consider gene 
mutation screening in early diagnosis and the follow-up of the clinical course in particular 
for the asymptomatic cases. Early determination of the disease causing mutation will be 
favorable in order to prevent abundant treatments in newly diagnosed patients. 
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